Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated commercial-stage biotechnology company, announced that members of its management team will participate in one-on-one meetings at BTIG's Infectious Disease Day 2026. The event will be held virtually on June 16, 2026. Seth Lederman, M.D., president and chief executive officer of Tonix Pharmaceuticals, will represent the company during the event.
Tonix Pharmaceuticals is focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company's flagship medicine, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first new treatment for fibromyalgia in more than 15 years. In addition to its CNS commercial infrastructure supporting marketed products such as Zembrace SymTouch and Tosymra for acute migraine, Tonix is advancing a pipeline of immunology programs. These include TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
The participation in BTIG's Infectious Disease Day 2026 underscores Tonix's commitment to addressing infectious diseases and immunology. The company's immunology pipeline is particularly noteworthy given the global burden of Lyme disease and the ongoing need for effective therapies to prevent transplant rejection. TNX-4800 aims to provide prophylaxis against Lyme disease, which affects hundreds of thousands of people annually. Meanwhile, TNX-1500 targets the CD40 ligand pathway, a key mechanism in immune response, to prevent kidney transplant rejection—a critical area given the thousands of transplants performed each year.
Tonix is also maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. Additionally, the company's CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. This breadth of pipeline highlights Tonix's strategy to leverage its expertise across CNS and immunology.
The BTIG Infectious Disease Day 2026 provides a platform for Tonix to discuss its immunology programs with investors and industry experts. The virtual format allows for broad participation, potentially increasing visibility for the company's late-stage candidates. For investors, this event offers an opportunity to gain insights into Tonix's development timelines and regulatory strategies.
Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication. The latest news and updates relating to TNXP are available in the company's newsroom at https://ibn.fm/TNXP. The full press release can be accessed at https://ibn.fm/38XUG.
